Grupo para la caracterización molecular de las neoplasias hematológicas
![Foto de Grupo para la caracterización molecular de las neoplasias hematológicas](/img/grupo.png)
![Foto de University Medical Center Utrecht](/img/noimage_org.png)
University Medical Center Utrecht
Utrecht, HolandaPublicaciones en colaboración con investigadores/as de University Medical Center Utrecht (7)
2022
-
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
New England Journal of Medicine, Vol. 386, Núm. 7, pp. 629-639
2021
-
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Leukemia, Vol. 35, Núm. 12, pp. 3585-3588
2020
-
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set
Blood, Vol. 136, Núm. 26, pp. 3033-3040
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2014
-
Combination of International Scoring System 3, highlactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death
Journal of Clinical Oncology, Vol. 32, Núm. 20, pp. 2173-2180
2013
-
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: A meta-analysis of phase III randomized, controlled trials
Journal of Clinical Oncology, Vol. 31, Núm. 26, pp. 3279-3287